When reflecting on the licensing deals inked this year by biotech behemoth Genentech Inc., two really stand out: the June deal with microbiome company Microbiotica Ltd. to discover, develop and commercialize treatments for inflammatory bowel disease (IBD), (Also see "Genentech Mines The Microbiome Again With IBD Deal" - Scrip, 7 June, 2018.) and the collaboration signed with Germany’s Affimed NV to develop and commercialize novel natural killer (NK) cell engager-based immunotherapeutics to treat multiple cancers. (Also see "Roche Pact Is Affirmation Of Affimed Technology " - Scrip, 28 August, 2018.)
Genentech's Immunology/Infectious Disease Deal Maker On Following The Science
Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Business
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.